$ADCT News

ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcript

ADC Therapeutics Announces Topline Data From Phase 3 LOTIS-5 Confirmatory Trial Evaluating ZYNLONTA In Combination With Rituximab In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics SA 2026 Q1 - Results - Earnings Call Presentation

RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

ADC Therapeutics (ADCT) Q4 2025 Earnings Call Transcript

ADC Therapeutics S.A. Q1 2026 Earnings Call Summary

ADCT Q1 2026 Earnings Call Transcript

Full Transcript: ADC Therapeutics Q1 2026 Earnings Call

ADC Therapeutics Q1 Earnings Call Highlights

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

ADC Therapeutics SA (NYSE:ADCT) Beats Q1 Estimates, But Market Reaction Remains Subdued

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript

ADC Therapeutics Q1 Adj. EPS $(0.13) Beats $(0.21) Estimate, Sales $20.851M Beat $19.240M Estimate

Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

ADC Therapeutics Announces New Employee Inducement Grant

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?